HE4 as a biomarker for diagnosis of lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HE4 as a biomarker for diagnosis of lung cancer

Published:2019-09 Issue:39 Volume:98 Page:e17198
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

He Yong-Peng,Li Li-Xian,Tang Jia-Xi,Yi Lin,Zhao Yi,Zhang Hai-Wei,Wu Zhi-Juan,Lei Hai-Ke,Yu Hui-Qing,Nian Wei-Qi,Gan Lin

Funder

The Foundation of CSTC

Special Performance Incentive and Guidance for Research Institutes of Chongqing

Health Bureau of Chongqing

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference39 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

2. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level;Chen;Chin J Cancer Res,2017

3. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

4. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries;Allemani;Lancet,2018

5. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann Oncol,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer;The Clinical Respiratory Journal;2024-05

2. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150;Tumor Biology;2023-08-02

3. Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022;Cancer Innovation;2023-05-19

4. Value of human epididymis secretory protein 4 in differentiating malignant from benign pleural effusion: an analysis of two cohorts;Therapeutic Advances in Respiratory Disease;2023-01

5. Evaluation of HE4 as a prognostic biomarker in uterine cervical cancer,;Cancer Treatment and Research Communications;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3